Anti-hTNF-α-hIgA2
| Product | Unit size | Cat. code | Docs. | Qty. | Price | |
|---|---|---|---|---|---|---|
|
Anti-hTNF-α-hIgA2 Human TNF-α (Adalimumab) antibody - Human IgA2 |
Show product |
100 µg 3 x 100 µg |
htnfa-mab7
|
|
Human IgA2 monoclonal antibody (mAb) against human TNF-α
Neutralizing monoclonal antibody against human TNF-α
Anti-hTNF-α-hIgA2 is a neutralizing monoclonal antibody (mAb) featuring the constant region of the human IgA2 (hIgA2) isotype and the variable region of adalimumab, a fully human therapeutic mAb that targets human tumor necrosis factor-alpha (hTNF-α). The variable region of adalimumab blocks the interaction of soluble and membrane-bound TNF-α with its receptors TFNR1 and TNFR2, thereby downregulating the inflammatory responses [1, 2].
Anti-hTNF-α-hIgA2 was generated by recombinant DNA technology. It is produced in CHO cells and purified by affinity chromatography with peptide M. The neutralizing activity of Anti-hTNF-α-hIgA2 was determined using recombinant human TNF-α and HEK-Blue™ TNF-α cells. TNF-α is a pleiotropic cytokine that notably induces NF-κB-mediated production of pro-inflammatory cytokines [1, 2].
Human IgA2 Isotype
The human IgA2 isotype is highly resistant to enzymatic degradation by bacterial proteases, due to a short hinge region. Human IgA2 displays low potency for Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and it does not mediate complement-dependent cytotoxicity (CDC).
Learn more about antibody isotype effector functions by reading our flyer on Clinically relevant monoclonal antibodies.
References:
1. Steeland S., et al. 2018. A new venue of TNF targeting. Int. J. Mol. Sci. 19:1442.
2. Shealy D.J. & Visvanathan S. 2008. Anti-TNF antibodies: lessons from the past, roadmap for the future. Therapeutic Antibodies (book). 101-129.
Figures
Specifications
Specificity: Human TNF-α (hTNF-α)
Clonality: Monoclonal antibody
Isotype: Human IgA2, kappa
Control: Anti-β-Gal-hIgA2
Source: Chinese hamster ovary (CHO) cells
Purification: Affinity chromatography with peptide M
Formulation: 0.2 µm filtered solution in TRIS buffer with glycine, saccharose, and stabilizing agents
Tested application: Blocking & Neutralization of hTNF-α signaling
Quality control:
- Human IgA2 isotype has been confirmed by ELISA.
- The neutralization of hTNF-α signaling pathway has been confirmed using cellular assays with the HEK-Blue™ TNF-α cells.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Contents
Anti-hTNF-α-hIgA2 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:
- htnfa-mab7: 100 µg
- htnfa-mab7-3: 3 x 100 µg
Product is shipped at room temperature.
Upon receipt, store lyophilized antibody at -20°C.
Details
Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine involved in necrotic and apoptotic cell death, cellular differentiation, inflammation, and regulation of immune cell activity [1]. TNF-α is mainly produced by activated monocytes, macrophages, and T cells. It is first synthesized as a membrane-bound molecule that forms a compact homotrimer through non-covalent interactions. The trimeric membrane-bound form is cleaved by tumor necrosis factor-alpha converting enzyme (TACE) releasing the soluble trimer [2]. Both the membrane-bound and soluble TNF-α bind homotrimeric transmembrane receptors, TNFR1 or TNFR2, triggering signaling pathways that involve TRADD, TRAF2, and RIP, and leading to the activation of NF-κB and MAPK pathways. Importantly, membrane-bound TNF can also mediate a reverse "outside-to-inside" signaling, although this mechanism remains to be fully elucidated [2].
References:
1. Steeland S., et al. 2018. A new venue of TNF targeting. Int. J. Mol. Sci. 19:1442.
2. Shealy D.J. & Visvanathan S. 2008. Anti-TNF antibodies: lessons from the past, roadmap for the future. Therapeutic Antibodies (book). 101-129.